A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC

Clinical trial NCT07586202 · RECRUITING

Trial details

NCT number: NCT07586202
Sponsor: Janssen Research & Development, LLC
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Carcinoma, Non-Small-Cell Lung

Start date: 2026-07-28
Primary completion: 2028-03-02
Enrollment: 68

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.